Signal Evaluation Under Uncertainty: Decision-Making When Evidence Is Incomplete

Introduction 

In pharmacovigilance, safety decisions rarely come with complete or definitive evidence. A potential safety signal may emerge from a small number of individual case safety reports (ICSRs), spontaneous reports, literature findings, clinical studies, epidemiological data, or other safety sources. At the time a signal is identified, the available evidence may be limited, inconsistent, or affected by important uncertainties. 

However, uncertainty does not mean that action should be delayed. 

The fundamental objective of signal evaluation is to determine whether the available evidence suggests a new or changed risk associated with a medicinal product and whether further investigation or regulatory action is warranted. This requires a structured approach that combines scientific assessment, clinical expertise, epidemiological thinking, data quality evaluation, and regulatory judgment. 

Effective signal management therefore depends not only on identifying potential signals, but also on understanding what the available evidence can—and cannot—demonstrate. 

A robust pharmacovigilance system should enable organizations to make proportionate, transparent, and well-documented decisions even when the evidence remains incomplete. 

Effective signal evaluation requires more than signal detection alone. It depends on structured validation, prioritization, scientific assessment, documentation, and appropriate follow-up as new evidence emerges. Baupharma’s signal management activities integrate these elements through structured methodologies, scientific expertise, and data-driven approaches, supporting the evaluation of emerging safety concerns and their potential implications for the product’s benefit-risk profile. 

1. What Is Signal Evaluation?

A safety signal can generally be understood as information suggesting a new potentially causal association, or a new aspect of a known association, between a medicinal product and an event that warrants further investigation. 

Signal evaluation is the process of assessing this information to determine: 

• Whether the observation represents a credible potential safety concern 

• Whether the evidence supports a causal relationship 

• Whether the issue is already adequately characterized 

• Whether additional analysis is required 

• Whether the signal should be confirmed, refuted, monitored, or escalated 

• Whether regulatory or risk-minimization action may be necessary 

Importantly, a signal is not proof of causality. 

The purpose of signal evaluation is not to immediately establish that a medicinal product caused an adverse event. Instead, it is to assess the strength, consistency, clinical relevance, and plausibility of the available evidence and determine the appropriate next step.

2. Why Signal Evaluation Is Challenging

Pharmacovigilance data are inherently complex. 

Spontaneous reporting systems may contain incomplete information, missing medical histories, concomitant medications, uncertain exposure dates, limited follow-up, duplicate reports, and variable reporting quality. 

In addition, the number of reports alone does not determine whether a signal is important. 

Several factors can complicate interpretation: 

• Under-reporting or stimulated reporting 

• Reporting biases 

• Confounding factors 

• Missing clinical information 

• Concomitant medicines 

• Indication-related effects 

• Background incidence of the event 

• Changes in exposure or utilization 

• Differences between populations 

• Variations in reporting practices between countries 

• Limited duration of available follow-up 

• Small numbers of cases for rare events 

Consequently, signal evaluation requires context rather than isolated data points.

3. The Signal Evaluation Process

A structured signal evaluation process can help organizations move from an initial observation to a scientifically and regulatorily defensible decision. 

A typical process includes: 

Detection → Validation → Prioritization → Evaluation → Decision → Action → Follow-up 

Each stage should be supported by appropriate documentation and quality controls.

4. Signal Validation: Is There a Genuine Safety Concern?

Before investing significant resources in a signal, the potential issue should be validated. 

Validation involves confirming that the underlying information is sufficiently credible to justify further assessment. 

Key validation activities 

The pharmacovigilance team may review: 

• Individual case reports 

• Medical narratives 

• Case seriousness 

• Patient demographics 

• Drug exposure 

• Time to onset 

• Dechallenge and rechallenge information 

• Relevant medical history 

• Concomitant medications 

• Laboratory or diagnostic findings 

• Duplicate cases 

• Follow-up information 

• Existing product safety information 

The team should also determine whether the event is already known and adequately characterized in the relevant safety documentation. 

Role of the PV case management team 

Case management teams are responsible for ensuring that relevant information is accurately captured, medically coded, quality checked and followed up where appropriate. 

Poor-quality case data can directly affect subsequent signal assessment. 

Role of the medical reviewer 

Medical review is particularly important when clinical interpretation is required. The reviewer can assess whether the clinical presentation is compatible with the suspected event and identify alternative explanations.

5. Evidence Assessment: Looking Beyond the Number of Cases

One of the most common misconceptions in signal evaluation is that a larger number of reports automatically represents stronger evidence. 

In reality, the quality and context of the evidence are often more important than the absolute number of cases. 

A small number of well-documented, clinically coherent cases may warrant more attention than a large number of poorly documented reports. 

Important dimensions of evidence assessment include: 

Temporal relationship 

Did the event occur within a biologically plausible timeframe following exposure? 

Biological plausibility 

Is there a reasonable pharmacological or biological mechanism that could explain the association? 

Dechallenge and rechallenge 

Did the event improve after discontinuation? Did it recur after re-exposure? 

These elements may provide useful supporting evidence, although their interpretation depends heavily on the clinical circumstances. 

Alternative explanations 

Could the underlying disease, concomitant medication, lifestyle factors, or another medical condition explain the event? 

Consistency 

Are similar observations appearing across different cases, populations, countries, data sources, or studies? 

Dose-response relationship 

Where relevant, does the frequency or severity of the event appear to change with exposure? 

Signal evaluation should therefore consider the totality of evidence, rather than relying on a single indicator.

6. Managing Conflicting or Incomplete Evidence

Uncertainty becomes particularly challenging when different sources produce different conclusions. 

For example, spontaneous reports may suggest an association while clinical studies do not demonstrate an increased risk. 

This does not necessarily mean that one source is correct and the other is wrong. 

Different data sources answer different questions and have different strengths and limitations. 

The evaluator should therefore ask: 

• What does each data source demonstrate? 

• What are the limitations of each source? 

• Could differences be explained by population characteristics? 

• Is there a plausible explanation for conflicting findings? 

• Is the available evidence sufficient to reach a conclusion? 

• What additional information could reduce the uncertainty? 

The conclusion may appropriately remain: 

“The evidence is currently insufficient to confirm or refute the signal.” 

This is a scientifically valid outcome. 

The objective is not to eliminate uncertainty artificially, but to characterize and manage it appropriately.

7. Quantitative and Qualitative Evidence

Modern signal management increasingly combines quantitative screening with qualitative scientific assessment. 

Quantitative methods 

Depending on the applicable system and data source, quantitative approaches may identify disproportionate reporting or unusual reporting patterns. 

These methods can be useful for detecting patterns that may otherwise be difficult to identify manually. 

However, statistical disproportionality does not establish causality. 

A statistical signal may arise because of: 

• Reporting bias 

• Confounding 

• Increased awareness 

• Media attention 

• Changes in product utilization 

• Data-quality issues 

Qualitative assessment 

Scientific and medical review is therefore essential to understand the context behind the numerical observation. 

The strongest signal management systems combine data-driven detection with expert interpretation.

8. The Role of the QPPV and PV Leadership

The QPPV or equivalent responsible pharmacovigilance professional has a critical role in ensuring that signal evaluation is conducted appropriately within the pharmacovigilance system. 

Responsibilities may include: 

• Ensuring appropriate signal management procedures are established 

• Ensuring potential signals are assessed within defined timelines 

• Reviewing significant safety concerns 

• Ensuring appropriate escalation 

• Supporting regulatory communication 

• Ensuring adequate documentation 

• Confirming that conclusions are scientifically and procedurally justified 

• Ensuring follow-up actions are implemented 

• Maintaining oversight of outsourced signal management activities 

The QPPV does not necessarily perform every scientific assessment personally. 

However, the QPPV should have sufficient oversight to understand what was evaluated, how the conclusion was reached, what uncertainties remain, and whether appropriate action was taken.

9. Cross-Functional Responsibilities

Signal evaluation should not operate as an isolated pharmacovigilance activity. 

Depending on the nature of the signal, multiple functions may contribute. 

Pharmacovigilance 

PV teams coordinate the evaluation, review safety data, assess individual cases, perform signal management activities, and maintain documentation. 

Medical/Clinical 

Medical and clinical experts provide interpretation of disease mechanisms, clinical presentation, differential diagnosis, and medical plausibility. 

Epidemiology/Biostatistics 

These functions can support analyses of background incidence, observed versus expected events, risk factors, and epidemiological evidence. 

Regulatory Affairs 

Regulatory teams support assessment of applicable reporting obligations, authority communication, labeling implications, and regulatory submissions. 

Quality Assurance 

QA provides oversight of compliance with procedures, quality systems, deviations, CAPA, and inspection readiness. 

Clinical Development 

Where relevant, clinical development teams may provide information from ongoing or completed clinical studies and support evaluation of emerging risks. 

Effective governance ensures that responsibilities are clearly defined and that significant safety concerns are escalated appropriately.

10. Regulatory Decision-Making Under Uncertainty

Regulatory decision-making does not always require absolute scientific certainty. 

When a potential risk may have significant consequences for patients, authorities and marketing authorization holders may need to consider whether the available evidence justifies further action while uncertainty remains. 

Possible actions may include: 

• Continued routine monitoring 

• Enhanced monitoring 

• Additional case follow-up 

• Targeted literature review 

• Additional database analyses 

• Epidemiological studies 

• Additional clinical investigation 

• Updates to safety information 

• Risk-minimization measures 

• Regulatory communication 

• Updates to risk management activities 

The appropriate action should be proportionate to the level of concern and the potential impact on patients.

11. Documentation: Making the Decision Defensible

A scientifically sound conclusion is not sufficient if the decision-making process cannot be reconstructed. 

Signal evaluation documentation should clearly demonstrate: 

1. What triggered the evaluation 
2. What data were reviewed 
3. Which methodology was used 
4. What limitations were identified 
5. How alternative explanations were considered 
6. What the medical assessment concluded 
7. What uncertainties remained 
8. Why the final decision was reached 
9. What actions were assigned 
10. How follow-up will be performed 

This creates an appropriate audit trail and supports inspection readiness. 

A conclusion such as “no action required” should therefore not be treated as self-explanatory. 

The documentation should explain why no action was considered appropriate based on the evidence available at that time.

12. Signal Closure Does Not Always Mean the End

A signal may be closed following evaluation, but closure does not necessarily mean that the issue can never become relevant again. 

New information may emerge through: 

• Additional ICSRs 

• New clinical studies 

• Published literature 

• Regulatory databases 

• Epidemiological research 

• Post-marketing studies 

• Changes in product exposure 

• New information about the mechanism of action 

Therefore, closed signals should remain subject to appropriate ongoing pharmacovigilance activities. 

A previously closed signal may be reopened if new evidence materially changes the benefit-risk assessment.

13. Escalation: When Should Uncertainty Trigger Action?

One of the most important professional judgments in signal management is determining when uncertainty itself warrants escalation. 

Factors that may support escalation include: 

• Serious or life-threatening outcomes 

• High clinical severity 

• A potentially preventable risk 

• A vulnerable patient population 

• Consistent findings across multiple data sources 

• Strong biological plausibility 

• Evidence suggesting increased frequency or severity 

• Potential impact on a large, exposed population 

• Evidence that existing risk-minimization measures may be insufficient 

The principle should be: 

The greater the potential impact on patients, the lower the tolerance for unexplained uncertainty. 

This does not mean treating every uncertain signal as a confirmed risk. It means ensuring that uncertainty is actively managed rather than ignored.

14. Risk-Benefit Assessment

Signal evaluation should ultimately be connected to the product’s overall benefit-risk profile. 

A potential risk should not automatically be evaluated in isolation. 

The assessment may consider: 

• Severity of the potential event 

• Frequency or estimated incidence 

• Patient population affected 

• Disease severity 

• Therapeutic alternatives 

• Magnitude of therapeutic benefit 

• Availability and effectiveness of risk-minimization measures 

• Remaining uncertainties 

The outcome should support an informed assessment of whether the product’s benefit-risk balance remains acceptable and whether additional action is necessary.

15. Building a Robust Signal Management Procedure

Organizations should establish a documented signal management process that defines: 

Governance 

Who owns signal detection, validation, assessment, escalation, approval, and closure? 

Data sources 

Which safety databases, literature sources, clinical studies, external databases, and other information sources are reviewed? 

Frequency 

How frequently are different sources or products screened? 

Methodology 

Which quantitative and qualitative approaches are applied? 

Timelines 

What timelines apply to validation, evaluation, escalation, reporting, and follow-up? 

Escalation criteria 

What characteristics require immediate or expedited review? 

Documentation 

Where are assessments, decisions, supporting evidence, and action plans recorded? 

Quality oversight 

How are deviations, missed activities, and procedural weaknesses managed? 

A well-designed procedure should provide consistency without preventing scientific judgment.

16. The Importance of Human Judgment

Technology can significantly improve the speed and scale of signal detection, but human expertise remains essential. 

Automated systems can identify patterns. They cannot independently determine the clinical significance of every pattern. 

Experienced pharmacovigilance professionals must interpret: 

• Clinical context 

• Biological plausibility 

• Data quality 

• Confounding 

• Disease-related factors 

• Regulatory implications 

• Patient impact 

• Overall benefit-risk considerations 

The future of signal evaluation is therefore not about choosing between technology and human expertise. 

It is about combining data-driven detection with scientifically informed human judgment.

17. From Uncertainty to Actionable Knowledge

The ultimate purpose of signal evaluation is not simply to label a signal as “confirmed” or “not confirmed.” 

It is to transform incomplete safety information into an informed decision. 

A mature pharmacovigilance organization should be able to answer four fundamental questions: 

What do we know? 

The established evidence and observations. 

What do we not know? 

The remaining limitations and uncertainties. 

What could change our conclusion? 

The additional evidence that would meaningfully influence the assessment. 

What should we do now? 

The proportionate action required to protect patients and maintain regulatory compliance. 

This approach creates a structured pathway from uncertainty to action. 

Key Takeaways 

• A signal is not proof of causality; it is an observation requiring scientific evaluation. 

• Incomplete evidence does not justify inaction when a potential patient-safety concern exists. 

• Signal evaluation should consider the totality, quality, consistency, and limitations of available evidence. 

• Quantitative methods can identify patterns, but clinical and scientific judgment remain essential. 

• The QPPV provides critical oversight of signal management, escalation, documentation, and regulatory compliance. 

• Signal evaluation requires effective collaboration between PV, medical, epidemiology, regulatory, clinical, and quality functions. 

• Decisions should be proportionate to the potential risk and the level of uncertainty. 

• Every conclusion should be sufficiently documented to demonstrate how and why the decision was reached. 

• Signal closure does not necessarily mean permanent resolution; new evidence can change the assessment. 

• Ultimately, effective signal management transforms incomplete evidence into informed, transparent, and patient-focused safety decisions.